U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.03 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.62 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,812.50
    -18.70 (-1.02%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.35%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.17%)
     
  • BTC-USD

    41,212.58
    -164.10 (-0.40%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.81 (-1.80%)
     

Quest Diagnostics (DGX) Expands Testing Access With CLX Pact

·3 min read

Quest Diagnostics Incorporated DGX recently entered into a collaboration with CLX Health to offer access to COVID-19 molecular diagnostic testing (PCR/NAAT) for people looking to attend live events nationwide or travel from the United States to destinations around the world. The testing will be available through CLX Health's TrustAssure Global Testing Platform.

It is worth mentioning that Quest Diagnostics is the first national COVID-19 molecular diagnostic testing provider to participate in the TrustAssure platform in the United States.

The latest collaboration is likely to expand Quest Diagnostics’ COVID-19 testing reach globally.

More in the News

CLX Health is a developer of cloud-based solutions which manages a COVID-19 testing ecosystem of physicians, clinics, hospitals, laboratories, and consumers with its TrustAssure Global Network.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

The TrustAssure platform helps the world's largest airlines and event venues by offering passengers access to authorized COVID testing locations globally. Many leading airlines have incorporated the TrustAssure Lab Platform to provide their customers an easy-to-use option to meet the testing requirements.

Individuals will be able to schedule appointments for molecular COVID-19 tests at select Quest Diagnostics patient service centers and more than 750 retail partner pharmacy locations across the United States through the TrustAssure Global Testing Platform. The results will be provided within 48 hours and in advance of an event or travel.

Significance of the Collaboration

Per management, as COVID-19 restrictions are lifted around the country and world, the partnership with TrustAssure will enable Quest Diagnostics to facilitate high-quality testing for individuals looking to get back to recreation and travel.

Notable Developments

In May 2021, Quest Diagnostics, as part of its continual process of development related to COVID-19 testing services, announced that it has expanded eligibility for $0 out-of-pocket COVID-19 testing through QuestDirect. Per this plan, adults can ask for access to the company's $0 out-of-pocket COVID-19 test option for themselves as well as for four years or older children through QuestDirect.

In the last-reported first quarter of 2021, despite declining demand for Quest Diagnostics’ COVID-19 testing services, the company performed an average of 101,000 COVID-19 molecular tests per day. Overall, in the first quarter, approximately 9.1 million molecular tests and nearly 900,000 serology tests were performed, contributing nearly 21% to volume growth.

Price Performance

Shares of the company have gained 5.9% in a year’s time against the industry’s fall of 16.8%.

Zacks Rank and Key Picks

Currently, the company carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the broader medical space are Envista Holdings Corporation NVST, BellRing Brands, Inc. BRBR and Laboratory Corporation of America Holdings or LabCorp LH, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.

Envista Holdings has an estimated long-term earnings growth rate of 26%.

BellRing Brands has an estimated long-term earnings growth rate of 22%.

LabCorp has a projected long-term earnings growth rate of 11%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report

Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report

Envista Holdings Corporation (NVST) : Free Stock Analysis Report

BellRing Brands, Inc. (BRBR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research